Abacavir/lamivudine combination in the treatment of HIV: a review

Figures & data

Table 1 Pharmacokinetics of abacavir (ABC) and lamividine (3TC) in adults

Pharmacokinetic property	ABC	3TC
Oral bioavailability (%)	83	82–86
Cmax (μg/ml)	4.26	2.04
Mean time to Cmax (hours)	0.7–1.7	0.5–1.5
AUC (μg *h/mL)	11.95	8.87
Plasma protein binding (1%)	50	<36
Plasma T1/2 (hours)	1.5	5–7
Intracellular T 1/2 (hours)	20.64	16–19
Metabolism	Predominantly hepatic metabolism and then renal excretion (about 83%); 2% of the drug renally excreted as unchanged drug	5%–10% hepatic metabolism; predominantly renal excretion as unchanged drug via organic cationic transportation